Abstract
In the United States, real-world evidence on apalutamide (APA) for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) is limited. This study describes prostate-specific antigen (PSA) response and treatment persistence among patients with mCSPC initiated on APA, with stratifications for Black/non-Black patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
